Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition

Sponsor
University Hospital, Essen
Study ID
NCT04619316
Phase
PHASE2
Status
Unknown

Conditions

  • Metastatic Thyroid Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a prospective interventional trial that aims to restore iodine incorporation in tumoral lesions of patients with unresectable, radioiodine-refractory thyroid cancer.

Key Dates

Start date
Feb 5, 2018
Status verified
Jun 2023
Primary completion
Dec 31, 2024
Completion
Dec 31, 2024

Study Design

Enrollment
70 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Other: BRAF wild type
    In BRAF wild type patients trametinib 2mg (1-0-0) is applied daily over a time span of 3 weeks, then the effect is evaluated via 123I whole-body scintigraphy
  • Other: BRAF V600E Mutation
    In BRAF wild type patients trametinib 2mg (1-0-0) and dabrafenib 75mg (2-0-2) are applied daily over a time span of 3 weeks, then the effect is evaluated via 123I whole-body scintigraphy

Primary Outcome Measure

Proportion of patients with sufficiently increased tumoral iodine incorporation [ Time Frame: At the time point of 123I whole-body scintigraphy, 3 weeks after the start of redifferentiation therapy ]

Central Contacts

Related Studies